Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company based in New Haven, Connecticut, is focusing on innovative treatments for chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The company's lead investigational therapy, Haduvio™ (oral nalbuphine extended-release), is designed to target opioid receptors involved in cough reflex regulation, making it a distinct treatment option. Haduvio has demonstrated statistically significant reductions in cough frequency in clinical trials, marking it as a potential therapeutic breakthrough for patients experiencing this debilitating condition, particularly as no FDA-approved therapies currently exist for such patients.

On February 25, 2026, Trevi's President and CEO, Jennifer Good, along with CFO David Hastings, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, inviting insights into their ongoing efforts and vision for Haduvio. The chat is scheduled for 9:20 a.m. ET, and both executives will engage in investor meetings, enhancing the company's visibility among prospective investors.

Chronic cough significantly impacts the quality of life for approximately 150,000 U.S. patients with IPF, two-thirds of whom struggle with uncontrolled symptoms. Similarly, around 228,000 individuals with non-IPF ILD face similar challenges, emphasizing the urgent need for effective treatments. RCC, affecting 2-3 million U.S. patients, also remains an area of high unmet medical need, characterized by the persistence of cough despite treatment for underlying conditions.

As Trevi continues to work towards regulatory evaluations, it aims for Haduvio to offer relief to millions affected by chronic cough, thereby potentially transforming patient care in this space. For further updates, stakeholders can visit Trevi's website and follow their social media channels.

As Trevi Therapeutics, Inc. prepares to showcase its innovative investigational therapy, Haduvio™, at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, investors should closely monitor the developments around this clinical-stage biopharmaceutical company. The potential approval of Haduvio, designed to treat chronic cough related to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung diseases, and refractory chronic cough (RCC), presents a unique investment opportunity in a market marked by a high unmet medical need.

Haduvio has already demonstrated statistically-significant efficacy in reducing cough frequency in clinical trials, setting it apart as a pioneering therapy with no direct competition currently approved by the FDA for these conditions. With an estimated 150,000 patients suffering from IPF and 228,000 from non-IPF ILD, the market demand for effective intervention is substantial. The fact that approximately 60% of these patients experience uncontrolled chronic cough amplifies the urgency for new therapies.

Investors should also note the broader implications of Haduvio’s dual mechanism of action as a kappa agonist and a mu antagonist, which positions it as a versatile option for managing chronic cough linked to various underlying conditions. Furthermore, the absence of current FDA-approved therapies for RCC underscores the potential for Haduvio to capture a significant share of a market affecting 2-3 million U.S. patients.

The upcoming fireside chat featuring President and CEO Jennifer Good, alongside CFO David Hastings, will provide invaluable insights into Trevi’s strategy and progress. Attendees can gain deeper understanding of Haduvio’s developmental status and the company's commercial pathway. As such, investors should consider monitoring Trevi Therapeutics closely during this pivotal moment and potentially look to capitalize on any favorable news stemming from the conference.